Literature DB >> 30275777

Antithrombotic Therapy After Percutaneous Left Atrial Appendage Occlusion Using the WATCHMAN Device.

Homam Moussa Pacha1, Rama Hritani1, M Chadi Alraies2.   

Abstract

Entities:  

Year:  2018        PMID： 30275777      PMCID： PMC6162133          DOI： 10.31486/toj.18.0012

Source DB:  PubMed          Journal:  Ochsner J        ISSN： 1524-5012


× No keyword cloud information.
  6 in total

Review 1.  EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion.

Authors:  Bernhard Meier; Yuri Blaauw; Ahmed A Khattab; Torsten Lewalter; Horst Sievert; Claudio Tondo; Michael Glikson
Journal:  EuroIntervention       Date:  2015-01       Impact factor: 6.534

2.  Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry.

Authors:  Martin W Bergmann; Timothy R Betts; Horst Sievert; Boris Schmidt; Evgeny Pokushalov; Stephan Kische; Thomas Schmitz; Felix Meincke; Kenneth M Stein; Lucas V A Boersma; Hüseyin Ince
Journal:  EuroIntervention       Date:  2017-09-20       Impact factor: 6.534

3.  Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology).

Authors:  Vivek Y Reddy; Sven Möbius-Winkler; Marc A Miller; Petr Neuzil; Gerhard Schuler; Jens Wiebe; Peter Sick; Horst Sievert
Journal:  J Am Coll Cardiol       Date:  2013-04-10       Impact factor: 24.094

4.  Initial worldwide experience with the WATCHMAN left atrial appendage system for stroke prevention in atrial fibrillation.

Authors:  Peter B Sick; Gerhard Schuler; Karl Eugen Hauptmann; Eberhard Grube; Steve Yakubov; Zoltan G Turi; Gregory Mishkel; Steve Almany; David R Holmes
Journal:  J Am Coll Cardiol       Date:  2007-03-21       Impact factor: 24.094

5.  5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials.

Authors:  Vivek Y Reddy; Shephal K Doshi; Saibal Kar; Douglas N Gibson; Matthew J Price; Kenneth Huber; Rodney P Horton; Maurice Buchbinder; Petr Neuzil; Nicole T Gordon; David R Holmes
Journal:  J Am Coll Cardiol       Date:  2017-11-04       Impact factor: 24.094

6.  Efficacy and safety of left atrial appendage closure with WATCHMAN in patients with or without contraindication to oral anticoagulation: 1-Year follow-up outcome data of the EWOLUTION trial.

Authors:  Lucas V Boersma; Hueseyin Ince; Stephan Kische; Evgeny Pokushalov; Thomas Schmitz; Boris Schmidt; Tommaso Gori; Felix Meincke; Alexey Vladimir Protopopov; Timothy Betts; David Foley; Horst Sievert; Patrizio Mazzone; Tom De Potter; Elisa Vireca; Kenneth Stein; Martin W Bergmann
Journal:  Heart Rhythm       Date:  2017-05-31       Impact factor: 6.343
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.